Results 151 to 160 of about 473,209 (278)

Microbiome and Tumor Microenvironment Interactions: Advances From Ecological Niches to Precision Oncology

open access: yesCancer Nexus, EarlyView.
Tumor‐associated microbiota occupies spatially organized ecological niches and influence cancer progression by reshaping tumor‐cell signaling, metabolism, immunity, stromal remodeling, and therapeutic response. Integrating microbiome‐derived biomarkers, targeted microbial interventions, spatial multi‐omics, longitudinal monitoring, and AI may enable ...
Yiwen Zhang   +7 more
wiley   +1 more source

Long‐Term Prognosis, Residual Recurrence Risk, and Postoperative Management After Pathological Complete Response in Rectal Cancer

open access: yesCancer Nexus, EarlyView.
This graphical abstract summarizes the post‐pCR clinical pathway in locally advanced rectal cancer. After neoadjuvant radiotherapy and systemic therapy followed by surgery, patients achieving pCR (ypT0N0) generally have durable disease control, although residual risks of local and distant recurrence remain. Risk assessment, guideline‐based surveillance,
Jia‐ang Wang   +3 more
wiley   +1 more source

The Multiple Criteria Qualitative Value‐Based Pricing Framework “MARIE” for Novel Cell and Gene Therapy

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
When setting the price of cell and gene therapies in Japan, the factors considered include the manufacturing and operating costs of the new drug or a comparator, leading to discrepancies between price and values, in particular those specific to cell and gene therapies.
Akina Takami, Ataru Igarashi
wiley   +1 more source

Multiscale Modeling of an 8‐Week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients with Chronic Hepatitis C Virus Infection

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Bemnifosbuvir (BEM) and ruzasvir (RZR) are pan‐genotypic HCV polymerase (NS5B) and NS5A inhibitors, respectively. In a single‐arm study (NCT05904470), 215 treatment‐naïve, adherent participants with chronic HCV (with or without cirrhosis) received BEM 550 mg QD plus RZR 180 mg QD for 8 weeks.
Carolin Zitzmann   +4 more
wiley   +1 more source

Toward the Use of Real‐World Data for Regulatory and HTA Decision‐Making: Experiences and Recommendations from Six EU‐Funded Projects

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Real‐world data are increasingly important for regulatory and health technology assessment decision‐making, yet their effective use across Europe remains limited by technical, methodological, regulatory, and societal challenges. Drawing on the experiences of six Horizon Europe projects in the MetReal cluster, this review summarizes common barriers and ...
Martin Russek   +34 more
wiley   +1 more source

Home - About - Disclaimer - Privacy